A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-ranging study of the vitamin D analog DP001 in patients with
end-stage renal disease (ESRD). The primary goals of this 4-week Phase 2A study are to
identify an appropriate starting dose of DP001 to be used in subsequent studies in this
population and for evaluation of pharmacokinetics of DP001 in ESRD patients.